KellBenz Licenses Antibodies from AdnaGen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KellBenx has licensed antibodies from AdnaGen which it will use to develop non-invasive prenatal diagnostics, AdnaGen's parent company, OncoVista Innovative Therapies said today.

Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders," OncoVista said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.